Dan P. Zandberg

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

Ezra E.W. Cohen, R. Bryan Bell, Carlo Bifulco et al. · Journal for ImmunoTherapy of Cancer · 2019 · 738 citations · Full text

Medicine, Immunology, Oncology +13

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

Lillian L. Siu, Caroline Even, Éva Remenár et al. · JAMA Oncology · 2018 · 310 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

Dan P. Zandberg, Alain P. Algazi, Antonio Jimeno et al. · European Journal of Cancer · 2018 · 267 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

Charu Aggarwal, Amy Prawira, Scott Antonia et al. · Journal for ImmunoTherapy of Cancer · 2022 · 141 citations · Full text

Life Sciences, Immunology, Oncology +17